9s64
From Proteopedia
Jump to navigationJump to search
Human TEAD1 in complex with 2-(4-chloro-3-{3-methyl-5-[4-(trifluoromethyl)phenoxy]phenyl}-1H-pyrrolo[3,2-c]pyridin-1-yl)ethan-1-ol
| ||||||||||||
Structural highlights
Publication Abstract from PubMedAiming to identify novel inhibitors of YAP-TEAD-dependent transcription, we conducted a TEAD-reporter-based cellular screen, which yielded a 5-azaindole hit that significantly stabilized TEAD subtypes 2 and 4 in a thermal shift assay. During optimization, derivatives with diverse TEAD selectivity profiles were obtained, including pan-TEAD and TEAD3-sparing inhibitors. Atropisomers with stabilized binding conformations surprisingly resulted in TEAD2 selective inhibitors. Cellular potency in reporter and viability assays was enhanced through targeted structural modifications. The physicochemical and pharmacokinetic properties were improved by the introduction of heteroatoms and the reduction of aromaticity. Structure-based considerations inspired the generation of a pyrrolo-pyridinone scaffold with further optimized properties. In lung cancer xenograft studies, representatives from both substance classes demonstrated monotherapeutic antitumor activity. For one selected example, the combination effect with the KRAS(G12C) inhibitor sotorasib was demonstrated in vivo. Phenotypic Hit Identification and Optimization of Novel Pan-TEAD and Subtype-Selective Inhibitors.,Heinrich T, Gambardella A, Schwarz D, Petersson C, Gunera J, Garg S, Schneider R, Keil M, Grimmeisen L, Unzue Lopez A, Schilke H, Weitzel T, Kolb C, Diehl P, Doerfel B, Anlauf U, Reither V, Rettig C, Opelt B, Delp A, Wildner N, Musil D, Friedrich E, Burgdorf L, Fuchss T, Albers L, Sousa PMF, Freire F, M Bandeiras T, Wienke D J Med Chem. 2025 Nov 27;68(22):24603-24623. doi: 10.1021/acs.jmedchem.5c02602. , Epub 2025 Nov 10. PMID:41212049[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||||
This page was last modified 19:30, 10 February 2026.